SCHEMBL4480575

SCHEMBL4480575

CNC(=O)c1c2c(c(O)c(=O)n1CC(C)C)C(=O)N(Cc1ccc(F)c(Cl)c1)CC2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.35
AKR1B1 P15121 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
LIPG Q9Y5X9 1/20 0.34
EGLN1 Q9GZT9 2/20 0.33
FSCN1 Q16658 1/20 0.33
PTGER4 P35408 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
TNIK Q9UKE5 1/20 0.32
GPR52 Q9Y2T5 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481021 0.88 AKR1B1 (0.35) AKR1B1ALDH1A1HSD17B10HDAC1HDAC6
SCHEMBL5446552 0.87 POLB (0.38) POLBAKR1B1HDAC1HDAC6EGLN1
SCHEMBL4491562 0.80 PTGS1 (0.34) AKR1B1ALDH1A1HTR2AHTR2CHTR2B
SCHEMBL4489034 0.80 AKR1B1 (0.38) AKR1B1HDAC1HDAC6HTR2A
SCHEMBL4499363 0.79 AKR1B1 (0.35) AKR1B1HDAC1HDAC6HTR2AHTR2C
SCHEMBL4487189 0.79 KMT2A (0.36) AKR1B1ALDH1A1PTGS1PTGS2
SCHEMBL13672787 0.79 AKR1B1 (0.38) AKR1B1ALDH1A1FSCN1HTR2ATNIK
SCHEMBL1335818 0.79 AKR1B1 (0.36) AKR1B1HDAC1HDAC6LIPGFSCN1
SCHEMBL4478160 0.78 MEN1 (0.39) AKR1B1ALDH1A1FSCN1
SCHEMBL2113536 0.78 AKR1B1 (0.35) AKR1B1HTR2ATNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
WO-2005087767-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed
WO-2005087767-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H POLB 25/4885AKR1B1 2248/4885ALDH1A1 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.